A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis

In this phase 2 placebo-controlled trial, peresolimab, a humanized monoclonal antibody that stimulates the programmed cell death protein 1 inhibitory pathway, showed efficacy in adults with rheumatoid arthritis.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-05, Vol.388 (20), p.1853-1862
Hauptverfasser:	Tuttle, Jay, Drescher, Edit, Simón-Campos, Jesus Abraham, Emery, Paul, Greenwald, Maria, Kivitz, Alan, Rha, Hyungmin, Yachi, Pia, Kiley, Christina, Nirula, Ajay
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Adult Allergy Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - administration & dosage Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Apoptosis Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Autoimmune Disease C-reactive protein Cell death Disease Double-Blind Method Drug Therapy, Combination Homeostasis Humans Immunoglobulin G Immunology Immunology General Inflammatory Disease Inflammatory diseases Joint diseases Lymphocytes Magnetic resonance imaging Monoclonal antibodies Pathogenesis Patients PD-1 protein Placebos Programmed Cell Death 1 Receptor - agonists Proteins Remission (Medicine) Rheumatoid Arthritis Rheumatology Rheumatology General Severity of Illness Index T-Cells Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this phase 2 placebo-controlled trial, peresolimab, a humanized monoclonal antibody that stimulates the programmed cell death protein 1 inhibitory pathway, showed efficacy in adults with rheumatoid arthritis.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2209856